Summary
This narrative review examines emerging pharmacological and therapeutic approaches for the prevention and treatment of preeclampsia, a pregnancy-specific disorder affecting 4–10% of pregnancies with significant maternal and foetal mortality risk. The authors highlight that whilst preeclampsia pathomechanism involves inflammation, oxidative stress, and endothelial dysfunction, no single key regulatory player has been identified, limiting the effectiveness of current therapies and necessitating premature delivery as the only definitive treatment. The review synthesises preclinical and clinical trial evidence for novel agents and methods, presenting their molecular targets as a foundation for future therapeutic development.
UK applicability
The findings are relevant to UK obstetrical practice, as preeclampsia remains a leading cause of maternal morbidity and mortality in the United Kingdom. Novel preventive and therapeutic strategies identified in this review could inform development of evidence-based clinical guidelines and reduce reliance on emergency delivery in the UK National Health Service.
Key measures
Molecular targets of tested agents and methods; efficacy of preventive and therapeutic interventions across preclinical and clinical trial stages
Outcomes reported
The review identifies and evaluates emerging preventive methods and therapeutic agents for preeclampsia, focusing on their molecular targets and current evidence status from preclinical and clinical trial phases. It presents novel pharmacological strategies not yet endorsed by major obstetrical and gynaecological societies.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.